Related Experiment Video
Updated: Jul 15, 2026

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation
Published on: July 6, 2019
Lipid A fraction of LPS induces a discrete MAPK activation in acute lung injury
Wen-Feng Fang1, Jae Hwa Cho, Qianbin He
1Divisio of Pulmonary Sciences and Critical Care Medicine, University of Colorado at Denver, Health Sciences Center, Denver, CO 80204, USA.
Abstract:
Lipopolysaccharide (LPS) induces acute lung injury (ALI) via Toll-like receptor 4 (TLR4)-mediated MAPK activation. The lipid A fraction of LPS is considered to be the active moiety, but whether the lipid A-TLR4 interaction accounts completely for ALI-associated MAPK activation in vivo has not been determined. The lipid A fraction of LPS induces a discrete MAPK activation pattern in murine ALI. Mice (C57BL/6J, C3H/HeJ) were treated with intratracheal instillations of purified lipid A or LPS (10, 30, and 100 microg per mouse) or vehicle. ALI was assessed by histology. Chromogenic myeloperoxidase (MPO) activity was measured in lung homogenates. MAPK expression was quantified by immunoblotting. In vitro ERK inhibitor studies using thioglycollate-elicited macrophages were also performed. MPO increased in a dose- and time-responsive fashion. Notably, MPO was 2.4-fold greater after lipid A compared with LPS and vehicle at 6 h after instillation (lipid A, 0.88 +/- 0.25 vs. LPS, 0.37 +/- 0.21 optical density units.min(-1).mg(-1); P < 0.05). However, ALI scores were comparable at 6 and 24 h between LPS and lipid A. MPO was also comparable in vehicle-treated or C3H/HeJ mice treated with LPS or lipid A at 6 and 24 h. Phospho-ERK activation was pronounced at 6 and 24 h after lipid A but not LPS treatment. In vitro studies confirmed the relationship between phospho-ERK activation and cytokine expression in macrophage stimulated with either LPS or lipid A. Compared with whole LPS, the lipid A fraction is associated with amplified whole lung MPO and ERK activation 6 h after intratracheal instillation in mice.
Insights
Lipopolysaccharide's lipid A fraction amplifies lung inflammation and ERK activation in mice, distinct from whole LPS. This suggests lipid A drives specific inflammatory responses in acute lung injury.
Area of Science:
- Immunology
- Pulmonology
- Molecular Biology
Background:
- Lipopolysaccharide (LPS) triggers acute lung injury (ALI) through Toll-like receptor 4 (TLR4) and MAPK pathways.
- The lipid A component of LPS is recognized as the primary active moiety.
- The precise role of lipid A in ALI-associated MAPK activation in vivo remains incompletely understood.
Purpose of the Study:
- To investigate the specific contribution of the lipid A fraction of LPS to MAPK activation and acute lung injury in a murine model.
- To compare the inflammatory and MAPK activation patterns induced by purified lipid A versus whole LPS.
Main Methods:
- Mice received intratracheal instillations of purified lipid A, LPS, or vehicle.
- Acute lung injury was assessed via histology.
- Myeloperoxidase (MPO) activity and MAPK (specifically ERK) expression were quantified in lung tissue.
- In vitro studies utilized macrophages to examine ERK activation and cytokine expression.
Main Results:
- Lipid A induced significantly higher MPO activity compared to LPS at 6 hours post-instillation.
- Despite increased MPO, ALI scores were comparable between lipid A and LPS treatments at 6 and 24 hours.
- Phospho-ERK activation was more pronounced following lipid A administration than LPS.
- In vitro, lipid A and LPS stimulated ERK activation and cytokine expression in macrophages.
Conclusions:
- The lipid A fraction of LPS induces amplified MPO activity and ERK activation in the lung compared to whole LPS.
- While lipid A drives specific inflammatory markers and MAPK activation, it results in ALI scores comparable to whole LPS.
- These findings highlight a distinct inflammatory profile associated with LPS lipid A in acute lung injury.
Related Concept Videos
Acute Inflammation I: Inflammatory Response
Formation of Lipopolysaccharides
Acute Inflammation II: Cellular Phase

